GR69153, a new parenteral cephalosporin, inhibited 90% of Escherichia coli, Klebsiella oxytoca, Proteus mirabilis, Citrobacter diversus, shigellae, and salmonellae at <0.25 ,ug/ml (MIC90). It had activity comparable to those of ceftazidime, cefpirome, cefepime, and E-1040. Against cephalosporinase-producing Enterobacter cloacae, Citrobacterfreundii, and Serratia marcescens, MICs ranged from 0.12 to >32 ,ug/ml, and cefpirome and cefepime were the most active agents against these species. Pseudomonas aeruginosa was highly susceptible to GR69153, and for this organism the MIC90 was <2 ,ug/ml, which was similar to the E-1040 MIC90, but most Pseudomonas cepacia and Xanthomonas maltophilia isolates were resistant. GR69153 inhibited Haemophilus influenzae and Moraxella branhamella at .0.5 ,ug/ml. For Staphylococcus aureus GR69153 MICs were similar to those of ceftazidime and E-1040. Enterococci and listeriae were resistant to GR69153, but Streptococcus pyogenes and Streptococcus pneumoniae were inhibited by 0.5 ,ug/ml. The activity of GR69153 was not affected by serum. GR69153 was not inactivated by the I8-lactamases of Staphylococcus aureus, TEM-1, TEM-2, SHV-1, and BRO-1, but it was hydrolyzed by TEM-3, TEM-9, and morganellae. GR69153 had overall activity comparable to those of commercially available parenteral cephalosporins or those found in clinical investigations. It is more active against bacteroides than most available aminothiazolyl parenteral cephalosporins are. GR69153 is hydrolyzed by the new plasmid j8-lactamases, and thus, its primary value may be related to its pharmacological properties.
Cephalosporin antibiotics have played an increasingly important role in the therapy of infections (1) . Synthesis of compounds that are not hydrolyzed by common ,-lactamases and that have good pharmaceutical properties has been the goal of recent research. The compound GR69153 ( Fig. 1 ) is a new aminothiazolyl cephalosporin which has preliminarily been reported to have excellent antimicrobial activity and to have a long serum half-life, approximately 4 h (2). This agent is actively transported into gram-negative bacteria by the iron transport system. We compared the in vitro activity of GR69153 with those of other cephalosporins and other agents against gram-positive and -negative bacteria.
MATERIALS AND METHODS
Bacterial strains. The majority of bacteria were routine clinical isolates collected at The Presbyterian Hospital in New York City over the past 2 years. Some isolates were saved because of their known resistance to beta-lactam antibiotics and were collected from patients treated in clinical trials of new cephalosporins. Some of these isolates were included in the general evaluation (see Table 1 ).
Characterized P-lactamase-producing strains were provided by laboratories in Europe and were used in the experiments only for stability.
Antimicrobial agents. GR69153 and ceftazidime were provided by Glaxo Inc., Research Triangle Park, N.C. Other standard antimicrobial reference powders were provided by the indicated pharmaceutical companies: cefpirome, Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.; cefepime, Bristol-Myers Squibb Co., Wallingford, Conn.; * Corresponding author. E-1040, Eisai Co., Ltd., Toyko, Japan; and piperacillin, Lederle Laboratories, Pearl River, N.Y. Gentamicin was purchased from Sigma Chemical Co., St. Louis, Mo. Susceptibility studies. MICs were determined by agar dilution methods, except as noted otherwise (3) . MuellerHinton agar was used for testing aerobic and facultative organisms. This was supplemented with 5% defibrinated sheep blood for testing streptococci. IsoVitaleX was added to chocolate blood agar for testing Neisseria, Haemophilus, and Moraxella species. Bacteroides species were tested on brucella agar supplemented with 5% sheep blood and vitamin K. Bacterial suspensions were prepared on fresh plates, placed into liquid medium, and applied to agar with a multipoint inoculating device to yield 104 CFU per spot for most organisms and 105 CFU per spot for anaerobes. Plates were incubated at 35°C in air, except for neisseriae, which were incubated in 5% C02, and anaerobes, which were incubated in an anaerobic environment (GasPak; BBL). MICs were determined after 18 h of incubation for aerobes and 48 h of incubation for anaerobes. Broth cultures in a volume of 1 determined by plating 0.01-ml samples from clear 1-ml tubes that of ceftazidime but was less active than E-1040, cefonto antibiotic-free agar plates. The MBC was the concenpirome, and cefepime against Enterobacter species and tration at which there was a 99.9% reduction in CFU based Citrobacterfreundii. GR69153 was less active than the other on the CFU in original samples, as determined by the cephalosporins against Morganella morganii. For approximethod of Pearson et al. (5) . For determination of pH mately 10% of the isolates of Proteus rettgeri, Providencia effects, the pH of Mueller-Hinton agar was adjusted with stuartii, and Serratia marcescens, GR69153 MICs were 2 hydrochloric acid or sodium hydroxide to the desired levels. jig/ml. Salmonella and Shigella species at .0.25 p.g/ml. Against and did not inhibit methicillin-resistant staphylococci. these species, GR69153 had activity comparable to those of GR69153 was less active than the other agents against group ceftazidime, cefpirome, cefepime, and E-1040; and it inhib-A streptococci, but 90% of the isolates were inhibited by 0.5 ited organisms resistant to piperacillin and gentamicin. For ,uglml, as were group B, C, F, and 0 streptococci. GR69153 some isolates of Klebsiella pneumoniae, Enterobacter spehad activity similar to that of ceftazidime against Streptocies, and Citrobacter freundii, as well as Morganella morcoccus pneumoniae but was less active than cefpirome, ganii, MICs were >8 ,ug/ml. GR69153 had activity similar to cefepime, and piperacillin. Similar to the other cephalospo- rins, GR69153 failed to inhibit Enterococcus faecalis and nas aeruginosa was 8-to 16-fold greater than the MIC. The Listeria monocytogenes.
GR69153 MBC determined in 50% human serum for Staph-GR69153 was more active than the other cephalosporins ylococcus aureus, Pseudomonas aeruginosa, Escherichia against Bacteroides fragilis and other Bacteroides species, coli, and Klebsiella pneumoniae (one isolate each) was inhibiting most Bacteroides at .8 ug/Iml, with the exception within a dilution of the MBC determined in Mueller-Hinton of Bacteroides thetaiotaomicron, for which the MIC was broth. The activity of GR69153 against Escherichia coli, >32 ,ug/ml. Peptostreptococci and peptococci (five isolates Klebsiella pneumoniae, and Staphylococcus aureus (five each; data not shown) were inhibited by .0.25 pg/ml.
isolates of each species tested) was similar in room air and in Clostridium perfringens was inhibited by 0.5 .g/nml, but for the anaerobic environment of the GasPak jar system.
Clostridium difficile the GR69153 MIC was 8 ,ug/ml. Propi-,I-Lactamase stability. The activity of GR69153 compared onibacterium species (four isolates; data not shown) were with those of the other agents against organisms with charinhibited by .0.25 ,ug of GR69153 per ml.
acterized of-lactamases is shown in Table 4 . With the excepEffect of growth conditions. The effect of inoculum size is tio erobacter loaceowhich c ins the cepshown in Table 2 . At 107 CFU there was an appreciable tion of Enterobacter cloacae, which contains the cephaloincrease in the MIC compared with the MIC at 105 CFU for sporinase P99, Escherichia coli, which contains TEM-9, and members of the family Enterobacteriaceae and Pseudomoa Citrobacter freundii isolate which possessed TEM-7 as nas aeruginosa. GR69153 was more active at pH 7.5 than it well as its own chromosomal 1-lactamase, all organisms was at pH 5.5 (Table 3) , with, for example, the mean MIC for were inhibited by <1 jxg/ml. GR69153 was not hydrolyzed by Pseudomonas aeruginosa increasing from 0.5 ,ug/ml at pH TEM-1, P99, Sabath-Abraham, Kl, CARB-1, CARB-4 (Dal-7.5 to 7 pLg/ml at pH 5.5 and increasing for one isolate from gleish), Staphylococcus aureus PC-1, or Moraxella BRO-1 1 to 64 ,ug/ml. There was a similar effect of pH on Serratia P-lactamases (Table 5 ). GR69153 was hydrolyzed by TEM-3, marcescens. There was no effect on the MIC for Staphylobut to a lesser degree than were cefotaxime and ceftazidime, coccus aureus. The GR69153 MBC for the members of the and for the Escherichia coli isolate containing TEM-9 (Table  family Enterobacteriaceae tested increased minimally com-4), the GR69153 MIC was 8 ,ug/ml. The MIC for E. coli pared with the MIC, but the GR69153 MBC for Pseudomocontaining TEM-3 was 0.25 ,ug/ml. GR69153 was less stable 4 h (2). GR69153 is a catechol-containing cephalosporin and, as such, can utilize the iron transport system in addition to porins to enter the periplasmic space. In this study, GR69153 was shown to have excellent activity against many members of the family Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus species, Moraxella species, and some anaerobic species. Against many members of the family Enterobacteriaceae, it had activity comparable to those of such agents as cefepime, cefpirome, and E-1040; and against some organisms its activity was superior to that of ceftazidime. GR69153 had poor activity against Enterobacter cloacae and Citrobacter freundii, which have derepressed 13-lactamase production, and some Morganella morganji isolates were resistant, which may be a result of 1-lactamase.
It was hoped that the presence of the catechol on the acyl side chain would allow enough of the compound to enter into the periplasmic space to inhibit 3-lactamase-producing En- terobacter species, but this did not seem to be possible. It is probable that the catechol function which utilizes iron transport contributes to the excellent activity of GR69153 against Pseudomonas aeruginosa. As with most cephalosporins, at a high inoculum the MICs for Pseudomonas aeruginosa are increased, and MBCs are higher than the MICs at an inoculum of 105 CFU/ml.
Although GR69153 is not destroyed by many of the clinically important 3-lactamases such as TEM-1 present in members of the family Enterobacteriaceae, Haemophilus species, and Neisseria species, the common chromosomal Klebsiella P-lactamase, and Staphylococcus aureus and Moraxella 1-lactamases, it does undergo some hydrolysis by the new TEM enzymes which hydrolyze cefotaxime, ceftazidime, and aztreonam. GR69153 inhibited Klebsiella pneumoniae isolates that contained the TEM-3 ,3-lactamases but not Enterobacter species when they contained the new enzymes as well as the normally present cephalosporinase.
GR69153 has the potential to be a useful antimicrobial agent because of its antibacterial spectrum and pharmacological properties and because it is active in the presence of human serum and at pH values that exist in most body compartments. The ultimate role of the compound will be determined by further study of its toxicological and clinical properties.
